Muscle  ||| S:0 E:7 ||| NN
wasting  ||| S:7 E:15 ||| NN
in  ||| S:15 E:18 ||| IN
disease ||| S:18 E:25 ||| NN
:  ||| S:25 E:27 ||| :
molecular  ||| S:27 E:37 ||| JJ
mechanisms  ||| S:37 E:48 ||| NNS
and  ||| S:48 E:52 ||| CC
promising  ||| S:52 E:62 ||| JJ
therapies  ||| S:62 E:72 ||| JJ
Atrophy  ||| S:72 E:80 ||| NNP
occurs  ||| S:80 E:87 ||| VBZ
in  ||| S:87 E:90 ||| IN
specific  ||| S:90 E:99 ||| JJ
muscles  ||| S:99 E:107 ||| NNS
with  ||| S:107 E:112 ||| IN
inactivity  ||| S:112 E:123 ||| NNS
( ||| S:123 E:124 ||| -LRB-
for  ||| S:124 E:128 ||| IN
example ||| S:128 E:135 ||| NN
,  ||| S:135 E:137 ||| ,
during  ||| S:137 E:144 ||| IN
plaster  ||| S:144 E:152 ||| NN
cast  ||| S:152 E:157 ||| VBD
immobilization ||| S:157 E:171 ||| CD
)  ||| S:171 E:173 ||| -RRB-
or  ||| S:173 E:176 ||| CC
denervation  ||| S:176 E:188 ||| NNS
( ||| S:188 E:189 ||| -LRB-
for  ||| S:189 E:193 ||| IN
example ||| S:193 E:200 ||| NN
,  ||| S:200 E:202 ||| ,
in  ||| S:202 E:205 ||| IN
patients  ||| S:205 E:214 ||| NNS
with  ||| S:214 E:219 ||| IN
spinal  ||| S:219 E:226 ||| JJ
cord  ||| S:226 E:231 ||| NN
injuries ||| S:231 E:239 ||| NNS
) ||| S:239 E:240 ||| -RRB-
.  ||| S:240 E:242 ||| .
Muscle  ||| S:242 E:249 ||| NN
wasting  ||| S:249 E:257 ||| NN
occurs  ||| S:257 E:264 ||| VBZ
systemically  ||| S:264 E:277 ||| VBN
in  ||| S:277 E:280 ||| IN
older  ||| S:280 E:286 ||| JJR
people  ||| S:286 E:293 ||| NNS
( ||| S:293 E:294 ||| -LRB-
a  ||| S:294 E:296 ||| DT
condition  ||| S:296 E:306 ||| NN
known  ||| S:306 E:312 ||| VBN
as  ||| S:312 E:315 ||| IN
sarcopenia ||| S:315 E:325 ||| CD
) ||| S:325 E:326 ||| -RRB-
;  ||| S:326 E:328 ||| :
as  ||| S:328 E:331 ||| IN
a  ||| S:331 E:333 ||| DT
physiological  ||| S:333 E:347 ||| JJ
response  ||| S:347 E:356 ||| NN
to  ||| S:356 E:359 ||| TO
fasting  ||| S:359 E:367 ||| VB
or  ||| S:367 E:370 ||| CC
malnutrition ||| S:370 E:382 ||| NN
;  ||| S:382 E:384 ||| :
and  ||| S:384 E:388 ||| CC
in  ||| S:388 E:391 ||| IN
many  ||| S:391 E:396 ||| JJ
diseases ||| S:396 E:404 ||| NNS
,  ||| S:404 E:406 ||| ,
including  ||| S:406 E:416 ||| VBG
chronic  ||| S:416 E:424 ||| JJ
obstructive  ||| S:424 E:436 ||| JJ
pulmonary  ||| S:436 E:446 ||| JJ
disorder ||| S:446 E:454 ||| NN
,  ||| S:454 E:456 ||| ,
cancer-associated  ||| S:456 E:474 ||| JJ
cachexia ||| S:474 E:482 ||| NN
,  ||| S:482 E:484 ||| ,
diabetes ||| S:484 E:492 ||| NN
,  ||| S:492 E:494 ||| ,
renal  ||| S:494 E:500 ||| JJ
failure ||| S:500 E:507 ||| NN
,  ||| S:507 E:509 ||| ,
cardiac  ||| S:509 E:517 ||| JJ
failure ||| S:517 E:524 ||| NN
,  ||| S:524 E:526 ||| ,
Cushing  ||| S:526 E:534 ||| NNP
syndrome ||| S:534 E:542 ||| NN
,  ||| S:542 E:544 ||| ,
sepsis ||| S:544 E:550 ||| NN
,  ||| S:550 E:552 ||| ,
burns  ||| S:552 E:558 ||| NNS
and  ||| S:558 E:562 ||| CC
trauma ||| S:562 E:568 ||| NN
.  ||| S:568 E:570 ||| .
The  ||| S:570 E:574 ||| DT
rapid  ||| S:574 E:580 ||| JJ
loss  ||| S:580 E:585 ||| NN
of  ||| S:585 E:588 ||| IN
muscle  ||| S:588 E:595 ||| NN
mass  ||| S:595 E:600 ||| NN
and  ||| S:600 E:604 ||| CC
strength  ||| S:604 E:613 ||| NN
primarily  ||| S:613 E:623 ||| RB
results  ||| S:623 E:631 ||| NNS
from  ||| S:631 E:636 ||| IN
excessive  ||| S:636 E:646 ||| JJ
protein  ||| S:646 E:654 ||| NN
breakdown ||| S:654 E:663 ||| NN
,  ||| S:663 E:665 ||| ,
which  ||| S:665 E:671 ||| WDT
is  ||| S:671 E:674 ||| VBZ
often  ||| S:674 E:680 ||| RB
accompanied  ||| S:680 E:692 ||| VBN
by  ||| S:692 E:695 ||| IN
reduced  ||| S:695 E:703 ||| JJ
protein  ||| S:703 E:711 ||| NN
synthesis ||| S:711 E:720 ||| NN
.  ||| S:720 E:722 ||| .
This  ||| S:722 E:727 ||| DT
loss  ||| S:727 E:732 ||| NN
of  ||| S:732 E:735 ||| IN
muscle  ||| S:735 E:742 ||| NN
function  ||| S:742 E:751 ||| NN
can  ||| S:751 E:755 ||| MD
lead  ||| S:755 E:760 ||| VB
to  ||| S:760 E:763 ||| TO
reduced  ||| S:763 E:771 ||| JJ
quality  ||| S:771 E:779 ||| NN
of  ||| S:779 E:782 ||| IN
life ||| S:782 E:786 ||| NN
,  ||| S:786 E:788 ||| ,
increased  ||| S:788 E:798 ||| VBN
morbidity  ||| S:798 E:808 ||| NN
and  ||| S:808 E:812 ||| CC
mortality ||| S:812 E:821 ||| NN
.  ||| S:821 E:823 ||| .
Exercise  ||| S:823 E:832 ||| NN
is  ||| S:832 E:835 ||| VBZ
the  ||| S:835 E:839 ||| DT
only  ||| S:839 E:844 ||| RB
accepted  ||| S:844 E:853 ||| VBN
approach  ||| S:853 E:862 ||| NN
to  ||| S:862 E:865 ||| TO
prevent  ||| S:865 E:873 ||| VB
or  ||| S:873 E:876 ||| CC
slow  ||| S:876 E:881 ||| JJ
atrophy ||| S:881 E:888 ||| NN
.  ||| S:888 E:890 ||| .
However ||| S:890 E:897 ||| RB
,  ||| S:897 E:899 ||| ,
several  ||| S:899 E:907 ||| JJ
promising  ||| S:907 E:917 ||| JJ
therapeutic  ||| S:917 E:929 ||| JJ
agents  ||| S:929 E:936 ||| NNS
are  ||| S:936 E:940 ||| VBP
in  ||| S:940 E:943 ||| IN
development ||| S:943 E:954 ||| NN
,  ||| S:954 E:956 ||| ,
and  ||| S:956 E:960 ||| CC
major  ||| S:960 E:966 ||| JJ
advances  ||| S:966 E:975 ||| NNS
in  ||| S:975 E:978 ||| IN
our  ||| S:978 E:982 ||| PRP$
understanding  ||| S:982 E:996 ||| NN
of  ||| S:996 E:999 ||| IN
the  ||| S:999 E:1003 ||| DT
cellular  ||| S:1003 E:1012 ||| JJ
mechanisms  ||| S:1012 E:1023 ||| NNS
that  ||| S:1023 E:1028 ||| WDT
regulate  ||| S:1028 E:1037 ||| VBZ
the  ||| S:1037 E:1041 ||| DT
protein  ||| S:1041 E:1049 ||| NN
balance  ||| S:1049 E:1057 ||| NN
in  ||| S:1057 E:1060 ||| IN
muscle  ||| S:1060 E:1067 ||| NNS
include  ||| S:1067 E:1075 ||| VBP
the  ||| S:1075 E:1079 ||| DT
identification  ||| S:1079 E:1094 ||| NN
of  ||| S:1094 E:1097 ||| IN
several  ||| S:1097 E:1105 ||| JJ
cytokines ||| S:1105 E:1114 ||| NN
,  ||| S:1114 E:1116 ||| ,
particularly  ||| S:1116 E:1129 ||| RB
myostatin ||| S:1129 E:1138 ||| JJ
,  ||| S:1138 E:1140 ||| ,
and  ||| S:1140 E:1144 ||| CC
a  ||| S:1144 E:1146 ||| DT
common  ||| S:1146 E:1153 ||| JJ
transcriptional  ||| S:1153 E:1169 ||| JJ
programme  ||| S:1169 E:1179 ||| NN
that  ||| S:1179 E:1184 ||| WDT
promotes  ||| S:1184 E:1193 ||| VBZ
muscle  ||| S:1193 E:1200 ||| JJ
wasting ||| S:1200 E:1207 ||| NN
.  ||| S:1207 E:1209 ||| .
Here ||| S:1209 E:1213 ||| RB
,  ||| S:1213 E:1215 ||| ,
we  ||| S:1215 E:1218 ||| PRP
discuss  ||| S:1218 E:1226 ||| VB
these  ||| S:1226 E:1232 ||| DT
new  ||| S:1232 E:1236 ||| JJ
insights  ||| S:1236 E:1245 ||| NNS
and  ||| S:1245 E:1249 ||| CC
the  ||| S:1249 E:1253 ||| DT
rationally  ||| S:1253 E:1264 ||| RB
designed  ||| S:1264 E:1273 ||| VBN
therapies  ||| S:1273 E:1283 ||| NNS
that  ||| S:1283 E:1288 ||| WDT
are  ||| S:1288 E:1292 ||| VBP
emerging  ||| S:1292 E:1301 ||| VBG
to  ||| S:1301 E:1304 ||| TO
combat  ||| S:1304 E:1311 ||| VB
muscle  ||| S:1311 E:1318 ||| JJ
wasting ||| S:1318 E:1325 ||| NN
.  ||| S:1325 E:1327 ||| .
